Tom3 schreef op 31 januari 2022 12:32:
Volgens mij is het redelijk zeker dat hij nieuwe data gaat onthullen. Schottelius is ingedeeld bij het hoofdstuk Unpublished Clinical Data Drop op dag 2
Unpublished Clinical Data Drop8:45 am Describing the Rationale Behind Innate Cell Engager and Cell Therapy Combination Studies, and Sharing Early Clinical Outcomes in Hodgkin Lymphoma
Arndt Schottelius
Chief Scientific Officer, Affimed
Synopsis
Outlining the innate and adaptive immune mechanisms to recognize and kill tumor cells, and the avenues for synergistic stimulation (crosstalk)
Describing the preclinical data which substantiates synergy between innate cell engager and immune cell functions to enhance in vivo mechanism of action
Comparing and contrasting the mode of action and early clinical evidence of AFM13 with NK cell therapies vs. checkpoint inhibitor and in monotherapy, and where promise lies to elicit maximum clinical benefit